Embecta Faces Securities Class Action Over Alleged Misrepresentation of Insulin Pen Needle Business
Hagens Berman, a national shareholder rights law firm, is investigating Embecta Corp. (NASDAQ: EMBC) for alleged violations of federal securities laws related to the company's insulin pen needle business. A class action lawsuit filed in the U.S. District Court for the District of New Jersey alleges that Embecta misled investors by overstating the stability and resilience of its core product line during a specific period from November 25, 2025, through May 4, 2026. The firm claims that Embecta's assurances were false as it was experiencing significant competitive losses at a major customer and declining market volume in the retail channel. On May 5, 2026, Embecta reported its second-quarter fiscal results revealing substantial revenue declines due to headwinds in the U.S. pen needle market. The company also cut its full-year adjusted EPS guidance by about 43% at the midpoint and reduced its quarterly dividend from $0.15 to $0.01 per share, causing a sharp drop of over 57.8% in stock price. Investors who purchased Embecta shares during this period are encouraged to report their losses for potential inclusion in the class action lawsuit.
Topics: class action lawsuit Embecta insulin pen needle business shareholder rights